1.91
price up icon3.24%   0.06
pre-market  プレマーケット:  1.87   -0.04   -2.09%
loading
前日終値:
$1.85
開ける:
$1.84
24時間の取引高:
1.12M
Relative Volume:
0.62
時価総額:
$101.50M
収益:
$832.00K
当期純損益:
$-135.12M
株価収益率:
-0.3136
EPS:
-6.09
ネットキャッシュフロー:
$-124.69M
1週間 パフォーマンス:
+17.90%
1か月 パフォーマンス:
+34.51%
6か月 パフォーマンス:
-14.73%
1年 パフォーマンス:
-74.97%
1日の値動き範囲:
Value
$1.805
$1.93
1週間の範囲:
Value
$1.75
$2.0793
52週間の値動き範囲:
Value
$1.30
$7.76

Inovio Pharmaceuticals Inc Stock (INO) Company Profile

Name
名前
Inovio Pharmaceuticals Inc
Name
セクター
Healthcare (1159)
Name
電話
(858) 410-3134
Name
住所
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Name
職員
134
Name
Twitter
@inoviopharma
Name
次回の収益日
2024-11-07
Name
最新のSEC提出書
Name
INO's Discussions on Twitter

INO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
INO
Inovio Pharmaceuticals Inc
1.91 100.97M 832.00K -135.12M -124.69M -6.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.46 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
598.16 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
467.55 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
663.73 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.97 37.96B 3.81B -644.79M -669.77M -6.24

Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-07-09 開始されました Piper Sandler Overweight
2024-05-14 開始されました Stephens Overweight
2024-01-25 アップグレード Oppenheimer Perform → Outperform
2022-11-09 ダウングレード Maxim Group Buy → Hold
2022-11-01 ダウングレード BofA Securities Neutral → Underperform
2022-07-19 再開されました RBC Capital Mkts Sector Perform
2022-05-11 ダウングレード Oppenheimer Outperform → Perform
2022-01-21 アップグレード BofA Securities Underperform → Neutral
2021-12-29 再開されました Jefferies Hold
2021-09-10 ダウングレード BofA Securities Neutral → Underperform
2021-06-24 開始されました Jefferies Hold
2021-03-23 開始されました BofA Securities Neutral
2021-02-12 開始されました Oppenheimer Outperform
2020-11-17 ダウングレード ROTH Capital Neutral → Sell
2020-11-10 アップグレード ROTH Capital Sell → Neutral
2020-09-28 ダウングレード Cantor Fitzgerald Overweight → Neutral
2020-09-28 アップグレード Maxim Group Hold → Buy
2020-07-01 ダウングレード Maxim Group Buy → Hold
2020-07-01 ダウングレード ROTH Capital Neutral → Sell
2020-06-29 ダウングレード H.C. Wainwright Buy → Neutral
2020-06-26 ダウングレード Stifel Buy → Hold
2020-05-21 開始されました The Benchmark Company Buy
2020-04-30 ダウングレード ROTH Capital Buy → Neutral
2020-03-13 ダウングレード Piper Sandler Overweight → Neutral
2020-03-13 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2019-12-19 開始されました ROTH Capital Buy
2018-02-15 繰り返されました Maxim Group Buy
2017-10-18 開始されました RBC Capital Mkts Outperform
2017-09-06 開始されました Citigroup Buy
2017-06-08 アップグレード Piper Jaffray Neutral → Overweight
2017-05-24 繰り返されました Maxim Group Buy
2017-03-16 アップグレード Maxim Group Hold → Buy
2017-03-16 ダウングレード Piper Jaffray Overweight → Neutral
すべてを表示

Inovio Pharmaceuticals Inc (INO) 最新ニュース

pulisher
Aug 20, 2025

INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow - MSN

Aug 20, 2025
pulisher
Aug 20, 2025

Inovio Pharmaceuticals (NASDAQ:INO) Given "Neutral" Rating at HC Wainwright - MarketBeat

Aug 20, 2025
pulisher
Aug 20, 2025

Inovio Pharmaceuticals (NASDAQ:INO) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 20, 2025
pulisher
Aug 19, 2025

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Aug 19, 2025
pulisher
Aug 19, 2025

Cervical Dysplasia Treatment Market Size Report 2034, - openPR.com

Aug 19, 2025
pulisher
Aug 17, 2025

Inovio aims for BLA submission and FDA file acceptance by year-end 2025 as 3107 data shows sustained surgery reduction - MSN

Aug 17, 2025
pulisher
Aug 16, 2025

Inovio Pharmaceuticals Inc. Recovery Linked to Earnings Surprise2025 Market Sentiment & Real-Time Buy Signal Alerts - newsyoung.net

Aug 16, 2025
pulisher
Aug 16, 2025

Momentum Screeners Rank Inovio Pharmaceuticals Inc. in Top 5 TodayLong Setup & Low Risk Entry Point Guides - newsyoung.net

Aug 16, 2025
pulisher
Aug 16, 2025

Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

INOVIO to Announce Q2 2025 Results on August 12 - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

INO.O Surges 13.9%: What's Behind Inovio Pharmaceuticals’ Intraday Spike? - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Inovio Pharmaceuticals shares surge 22.84% intraday after Q2 earnings report, BLA submission plan, and rating upgrade. - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Inovio Pharmaceuticals (INO) Surges 19.4% on Earnings Optimism—What's Fueling the Biotech Rally? - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Inovio Pharmaceuticals Soars 12.28% on Q2 Earnings, Clinical Progress - AInvest

Aug 15, 2025
pulisher
Aug 15, 2025

Inovio Pharmaceuticals Second Quarter 2025 Earnings: US$0.61 loss per share (vs US$1.19 loss in 2Q 2024) - Yahoo Finance

Aug 15, 2025
pulisher
Aug 15, 2025

Inovio rises after promising Q2 results - MSN

Aug 15, 2025
pulisher
Aug 14, 2025

Inovio Pharmaceuticals : Second Quarter 2025 Financial Results Conference Call Q2 2025 Financial Results Presentation - MarketScreener

Aug 14, 2025
pulisher
Aug 14, 2025

Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment - The Globe and Mail

Aug 14, 2025
pulisher
Aug 14, 2025

H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛

Aug 14, 2025
pulisher
Aug 14, 2025

Inovio Pharmaceuticals: HC Wainwright Raises PT to $3 from $3, Maintains Neutral Rating. - AInvest

Aug 14, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals’ SWOT analysis: dna immunotherapy firm’s stock faces pivotal year - Investing.com

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Q2 2025 Earnings Call Highlights: BLA Submission, Financial Challenges, and Regulatory Progress - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Inc. Stock Rallies 14.1%, Outperforms Competitors - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals shares rise 13.76% intraday after reporting Q2 2025 financial results and progress on INO-3107. - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Q2 Results: Net Loss Narrows to $0.61 per Share - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio rises after promising Q2 results (INO:NASDAQ) - Seeking Alpha

Aug 13, 2025
pulisher
Aug 13, 2025

Jefferies Upgrades Inovio Pharmaceuticals(INO.US) to Buy Rating, Cuts Target Price to $1.8 - 富途牛牛

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 13, 2025
pulisher
Aug 13, 2025

Jefferies lowers Inovio stock price target to $1.80 from $2.00 By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

JMP analyst reiterates Market Outperform rating on Inovio stock By Investing.com - Investing.com Canada

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals (INO) Targets BLA Submission for INO-3107 by Year-End 2025 - GuruFocus

Aug 13, 2025
pulisher
Aug 13, 2025

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights - BioSpace

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio’s 2025Q2 Earnings Call: Key Contradictions on Regulatory Strategy, Financial Health, and Clinical Trials - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Targets BLA Submission, FDA Approval by Year-End 2025 Amid Positive 3107 Trial Results - AInvest

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus

Aug 13, 2025
pulisher
Aug 13, 2025

Inovio Pharmaceuticals Reports Q2 2025 Financial Progress - TipRanks

Aug 13, 2025
pulisher
Aug 12, 2025

Inovio Pharmaceuticals 2025 Q1 Earnings Net Loss Narrows 35.4% - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Inovio: Q2 Earnings Snapshot - Big Rapids Pioneer

Aug 12, 2025
pulisher
Aug 12, 2025

Earnings call transcript: Inovio’s Q2 2025 sees reduced losses, stock rises - Investing.com

Aug 12, 2025
pulisher
Aug 12, 2025

Transcript : Inovio Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 12, 2025 - MarketScreener

Aug 12, 2025
pulisher
Aug 12, 2025

Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrow - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 - Eastern Progress

Aug 12, 2025
pulisher
Aug 12, 2025

INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights | INO Stock News - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

Inovio Pharmaceuticals Inc Reports Q2 2025 EPS of -$0.61, Narrowly Beating Estimates - GuruFocus

Aug 12, 2025
pulisher
Aug 12, 2025

INOVIO on track to submit BLA for INO-3107 in 2H25, FDA requested rolling submission. - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

INOVIO Reports Second Quarter 2025 Financial Results And Recent Business Highlights - Barchart.com

Aug 12, 2025
pulisher
Aug 12, 2025

Major Earnings Expected After the Close Tuesday: CoreWeave, Inovio Pharmaceuticals, Luminar Technologies, and More - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Options Volatility and Implied Earnings Moves Today, August 12, 2025 - TipRanks

Aug 12, 2025

Inovio Pharmaceuticals Inc (INO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$36.31
price down icon 1.55%
$86.53
price up icon 0.38%
$26.01
price up icon 0.54%
$110.77
price down icon 0.48%
$132.60
price up icon 2.43%
biotechnology ONC
$313.97
price up icon 1.50%
大文字化:     |  ボリューム (24 時間):